摘要
目的：观察紫杉醇联合萘达铂方案一线治疗晚期或手术／放疗后转移复发性食管癌患者的近期疗效和安全性。方法：给药方案为紫杉醇135～150mg／m^3，3h静脉滴入，d1；萘达铂80mg／m^3，2h静脉滴入，d2,每个周期为21d。疗效评估用RECIST疗效评价标准；不良反应评估用NCICTC3．0标准。结果：有效率（RR）50．0％（14／28），稳定率（SD）35．7％（10／28），进展率（PD）14．3％（4／28）。主要不良反应有粒细胞细胞下降78．6％（3／4度21．4％），贫血57．1％（3／4度10．7％），血小板下降50．0o．4（3／4度10．7％），恶心60．7％（3／4度7．1％），呕吐50．0％（3／4度3．6％），2例（7．1％）患者推迟化疗但均≤1周，无治疗相关性死亡。结论：紫杉醇联合萘达铂治疗晚期或手术／放疗后转移复发性食管癌具有较好的疗效且有较好的耐受性。
OBJECTIVE： To investigate the efficacy and toxicity of the combination of paclitaxel and nedaplatin as firstline chemotherapy for patients with metastatic esophageal cancer. METHODS： Patients with metastatic esophageal cancer received 135-150 mg/m2 of paclitaxel over a 3 h infusion（d1）, followed by nedaplatin 80 mg/m2 in a 2 h infusion（d2） every 3 weeks until the documented disease progression, unacceptable toxicity and patienfs refusal. RECIST and NCT CTC 3.0 systems were used to evaluate treatment outcome and side effect. RESULTS： The overall response rate was 50.0% （14/28）, SD was 35.7%（10/28）, and PD was 14.30/00（4/28）. Two patients （7.1%） were delayed for chemotherapy because of hematological toxicities no more than 1 week. The treatment was well tolerated and no toxic death occurred. CONCLUSION： Combination of paclitaxel and nedaplatin is a tolerable regimen with promising activity in previously untreated metastatic esophageal cancer.
出处
《中华肿瘤防治杂志》
CAS
2011年第1期60-62,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
安徽省自然科学基金(070413256X)
2008年安徽省临床医学应用技术项目(2008A054)
2010年省卫生厅医学科研课题(2010B001)
关键词
食管肿瘤/药物疗法
紫杉酚
药物疗法
联合
esophageal neoplasms/drug therapy paclitaxel drug therapy, combination
